Literature DB >> 34601944

Salivary CGRP can monitor the different migraine phases: CGRP (in)dependent attacks.

Alicia Alpuente1,2, Victor J Gallardo2, Laila Asskour2, Edoardo Caronna1,2, Marta Torres-Ferrus1,2, Patricia Pozo-Rosich1,2.   

Abstract

BACKGROUND: CGRP plays a key role in the transmission and modulation of nociceptive signals and is a critical component in the pathogenesis of migraine.
OBJECTIVE: To assess saliva as a substrate to measure CGRP by comparing interictal levels in patients with episodic migraine and controls; and to evaluate CGRP's temporal profile during migraine attacks.
METHODS: This prospective observational pilot study included young women with episodic migraine and healthy controls. We monitored salivary CGRP-like immunoreactivity (CGRP-LI) during 30 consecutive days and during migraine attacks. We considered six timepoints for the analysis: interictal (72h headache free), preictal (PRE-24h before the attack), ictal (headache onset, after 2h, after 8h), postictal (POST-24h after the attack). CGRP levels were quantified by ELISA.
RESULTS: 44 women (22 with episodic migraine, 22 healthy controls) were recruited. Differences in interictal salivary levels of CGRP between patients and controls (Me [IQR]: 98.0 [80.3] (95% CI 56.6, 124.0) vs. 54.3 [44.0] (95% CI 42.2, 70.1) pg/mL, p = 0.034) were found. An increase in CGRP levels during migraine attacks was detected (pre:169.0 [95% CI 104.2-234.0]; headache onset: 247.0 [181.9-312.0]; after 2h: 143.0 [77.6-208.0]; after 8h: 169.0 [103.5-234.0], post: 173.0 [107.8-238.0]). Patients were classified as having CGRP-dependent (79.6%) and non-CGRP dependent migraine attacks (20.4%) according to the magnitude of change between preictal and ictal phase. Accompanying symptoms such as photophobia and phonophobia were significantly associated to the first group.
CONCLUSIONS: Salivary CGRP-LI levels, which interictally are elevated in episodic migraine patients, usually increase during a migraine attack in the majority of patients. However, not every attack is CGRP-dependent, which in turn, might explain different underlying pathophysiology and response to treatment.

Entities:  

Keywords:  CGRP; ELISA; Migraine; migraine phases; saliva

Mesh:

Substances:

Year:  2021        PMID: 34601944     DOI: 10.1177/03331024211040467

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  6 in total

1.  Unpredictable Sound Stress Model Causes Migraine-Like Behaviors in Mice With Sexual Dimorphism.

Authors:  Fernanda Tibolla Viero; Patrícia Rodrigues; Julia Maria Frare; Náthaly Andrighetto Ruviaro Da Silva; Marcella de Amorim Ferreira; Ana Merian Da Silva; Gabriele Cheiran Pereira; Juliano Ferreira; Micheli Mainardi Pillat; Guilherme Vargas Bocchi; Romina Nassini; Pierangelo Geppetti; Gabriela Trevisan
Journal:  Front Pharmacol       Date:  2022-06-16       Impact factor: 5.988

2.  Cerebral Blood Flow and Other Predictors of Responsiveness to Erenumab and Fremanezumab in Migraine-A Real-Life Study.

Authors:  Magdalena Nowaczewska; Marcin Straburzyński; Marta Waliszewska-Prosół; Grzegorz Meder; Joanna Janiak-Kiszka; Wojciech Kaźmierczak
Journal:  Front Neurol       Date:  2022-05-17       Impact factor: 4.086

3.  The chicken and egg problem: CGRP release due to trigeminal activation or vice versa?

Authors:  Karl Messlinger
Journal:  Cephalalgia       Date:  2021-10-04       Impact factor: 6.292

Review 4.  CGRP and Migraine: What Have We Learned From Measuring CGRP in Migraine Patients So Far?

Authors:  Katharina Kamm
Journal:  Front Neurol       Date:  2022-07-27       Impact factor: 4.086

Review 5.  New Oral Drugs for Migraine.

Authors:  Nazia Karsan; Peter J Goadsby
Journal:  CNS Drugs       Date:  2022-08-29       Impact factor: 6.497

Review 6.  Hypoxia-related mechanisms inducing acute mountain sickness and migraine.

Authors:  Florian Frank; Katharina Kaltseis; Vera Filippi; Gregor Broessner
Journal:  Front Physiol       Date:  2022-09-06       Impact factor: 4.755

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.